Aspirin and anti-clotting drug's combo reduces dialysis access failure risk.Byline: ANI Washington, May 21 (ANI): A combination of aspirin and the anti-platelet drug dipyridamole dipyridamole /di·py·rid·a·mole/ (di?pi-rid´ah-mol) a platelet inhibitor and coronary vasodilator used to prevent thromboembolism associated with mechanical heart valves, to treat transient ischemic attacks, and as an adjunct in could significantly reduce blockages and extend the life of new artery-vein access grafts used for hemodialysis, according to study by the Dialysis Access Consortium (DAC See D/A converter and discretionary access control. DAC - Digital to Analog Converter ). Very often, artery-vein access grafts, called arteriovenous arteriovenous /ar·te·rio·ve·nous/ (-ve´nus) both arterial and venous; pertaining to or affecting an artery and a vein. ar·te·ri·o·ve·nous adj. Abbr. (AV) grafts, fail due to narrowing of blood vessels (stenosis) at the graft site and subsequent clotting, which block the flow of blood. And a blocked graft becomes useless for dialysis and is a major cause of worsening health in dialysis patients. In the DAC trial, the researchers observed that the combination treatment decreased the rate of loss of primary unassisted graft patency by 18 percent and the rate of developing significant stenosis by 28 percent, compared to placebo. Graft patency is the useful life of a graft before it becomes blocked the first time. "This drug combination provides a modest but important new therapy to keep AV grafts in good working order so patients can get the dialysis they needBut clearly more research is needed to extend the useful life of AV grafts," said Dr.Griffin P. Rodgers, Director National Institute of Diabetes and Digestive and Kidney Diseases About NIDDK The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), of the U.S. National Institutes of Health, conducts and supports research on many of the most serious diseases affecting public health. (NIDDK NIDDK National Institute of Diabetes and Digestive and Kidney Diseases ). The researchers enrolled 649 participants with new AV grafts were for the five-year long trial at 13 clinical sites in the United States. All the participants were randomly assigned to treatment with dipyridamole plus aspirin or to a placebo.Our trial results show that we now have a drug therapy that significantly prolongs the viability of AV grafts. This is an important step forward as we proceed to develop therapies to improve dialysis patients' quality of life," said Dr. Bradley S. Dixon, lead author of the study. The study has been published in the New England Journal of Medicine The New England Journal of Medicine (New Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely-read peer-reviewed general medical journals in the world. . (ANI) Copyright 2009 Asian News International The Asian News International (ANI) agency provides multimedia news to China and 50 bureaus in India. It covers virtually all of South Asia since its foundation and presently claims, on its official website, to be the leading South Asia-wide news agency. (ANI) - All Rights Reserved. Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion